Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I wasn’t on the tour, but I’ve been around a long time, since well before the 25-1 RS, ugh that was painful. I have a low cost basis, so I didn’t sell on the drop and am still in the green and I still believe there is a likely path to approval, but we’ll have to wait and see.
The company targeted H&N first because of an unmet need. The plan is to test on other cancers after approval for H&N. There is already some data (phase I or pre-clinical) on effectiveness for other cancers.
Hahaha. They must have checked out early on a Friday afternoon.
And don’t forget that Multikine received orphan drug designation from the FDA and 7 years of market exclusivity. Even if the parents expire, FDA won’t approve a competing product.
Yeah I know. I typically like everything else—food and drink—but I just can’t tolerate Bourbon.
The Macallan is good and I enjoy Highland Park, but my favorites are Islay Whiskeys Lagavulin, Laphroaig, etc.
Jefferson’s Ocean is the best Bourbon I’ve ever had, which is slightly better than the worst Scotch I’ve ever had.
I think Bourbon is just a practical joke the rest of the world is playing on me, because truthfully, that stuff is awful and I can’t see how anyone can like it.
Droid, I hope you do recoup your losses. I was shocked by both the results and the market reaction. However, I still see a clear path to approval, depending on the full results of the trial that we have to wait for until they’re published.
I haven’t sold anything yet, I’ve been in this a long time and have a low cost basis (averaged down after the 25-1 RS), so I’m still in the green. I took a gamble when investing in CVM and still believe it will pay off.
Spider, you summed it up beautifully. The only thing your post is missing is a mic drop at the end.
Same for me
Same. This pps is going to look good before long.
Great question on criteria for who does and does not receive chemo. I’m curious to find out the answer.
The number of patients who don’t receive chemo is 155,000 globally, according to the CVM press release.
155,000 patients * $100,000 per treatment is $15.5 billion in revenue. How is that not a success?
I know, but WTF? I can’t believe the price drop, but what else could it be, except manipulation? Even success in a subset is still success.
Manipulation, shorts are bringing the price down to cover before the news sinks in. Give it time and keep the faith.
And after the full medical review.
Nice
Yup, he’s always manipulating CVM and trying to control the narrative on this board.
Fosco,
Thanks for the analysis. Acquirers do like targets with lots of cash on hand.
I was also thinking that it’s been a long time since we had an update on LEAPS, do you think it’s possible, or even likely, that this cash raise could signal a new development with LEAPS? I have no evidence that this is the case—I’ll need to go back through the last updates on LEAPS, just speculating.
Good for you, teaching your kids to be better.
I certainly understand your point of view. It’s been a long long road for most of us CVM investors and the finish keeps getting pushed back.
I just try to stay focused on the fact that phase III results are all that really matter. Tweets, predictions, and over-analyzing every nugget are nice distractions while we wait, but really aren’t that important in the bigger picture of Multikine’s success or failure.
Thank Henkel. I really hope Geert has the last and largest laugh at the short’s expense.
@PT yes, I do think this is better. To me, his tweets countering shorts show that he believes in success and wants to rub it in the faces of the shorts. Not the high road, but I’m not a high road kind of guy.
Again, just my opinion, which doesn’t mean you and @Fluteman are wrong.
Ideally the shorts would all go away and Geert could focus only on business, but that is not the case here.
I’m with Trickle on Geert’s tweets. If he stays silent then the short narrative would be that “he says nothing because he knows it failed.”
Geert’s in a tough position with the shorts and I think he’s handling it the best he can. Just my opinion.
Thanks SAB
Agreed, in it until data—at least, probably longer if/when data is good.
I posted info on form 4’s from the SEC website, it specifically mentions a form 4 is required for transactions involving warrants.
What’s a Form 4?
In most cases, when an insider executes a transaction, he or she must file a Form 4. With this form filing, the public is made aware of the insider’s various transactions in company securities, including the amount purchased or sold and the price per share. Form 4 must be filed within two business days following the transaction date. Transactions in a company’s common stock as well as derivative securities, such as options, warrants, and convertible securities, are reported on the form. Each transaction is coded to indicate the nature of the transaction.
https://www.sec.gov/files/forms-3-4-5.pdf
If I remember correctly, the article was based off of S-1’s only and was refuted at the time, because no form 4’s were filed, which are required for an insider to buy or sell shares. It is my understanding that a form 4 needs to be filed, if warrants are exercised and then sold, but not if warrants are exercised and held.
If my understanding is correct, the article is garbage because no shares were sold, based on no form 4’s filed.
I’m going off memory and may be wrong, as I don’t have time to dig deeper right now.
It was either the work of a genius or an idiot. Either way the pps is up.
The grammatical errors, of which their were plenty (see what I did there), were not nearly as egregious as the logical errors.
The author failed to mention the many times the IDMC reviewed the trial and said to continue. The author lumped all clinical trials into a short time frame for data analysis without considering trial complexity. As already mentioned on this board, the author didn’t consider the time it took for data lock—which included a full medical review.
Or he’s a poor gambler with a rich poker habit. The point is, people sell investments to make money for lots of reasons. He has a track record of selling shares once or twice a year, which he is allowed to do.
It’s his money and he wants cash now. For him a little cash now is better than (maybe) a lot of cash later.
I don’t think one insider selling, with a history of selling shares, is a big deal. If several more start selling, then I would be concerned. Don’t forget, in tough times a lot of CVM execs took shares instead of salary.
This also tells us that he isn’t privy to non public knowledge, so CVM is still blinded.
Absolutely BULLISH!
Why? Dear God why did you ask him a question? Now he’s going to go into a rant about orange jumpsuits again.
In addition to the other responses you’ve received, the Multikine trial design allows patients to seek other treatments, like Keytruda, and still remain in the trial. This has been confirmed by CVM investor relations and discussed in-depth on this board.
Please do better DD before speculating.
Agreed. Mostly a binary event, but a little bit of a gray area just below the primary endpoint of 10% improvement in overall survival. The FDA has lowered the bar in the years since the Multikine trial was designed and anything above 8% may still receive approval, however there would be downward pressure on the pps, at least in the short term.
Hahaha, that sounds just like my one and only experience skiing—just replace beach house crew with Navy buddies and Colorado with Vermont. At first I tried to stay away from other skiers, there was this one area where no one else was, so I went down that part of the slope. Then I found out why... there were large mounds on the slope someone called “moguls” or something. I hit one and flew into the air and came down flat on my back. A lady said she never saw anything like it in over 20 years of skiing.
Water skiing is the only skiing I’ve done since. Ah, good memories. Thanks for sharing your story and reminding me of mine.
Yup, that’s where I am—wait and see. Not worried about the pps until data comes out.
Yeah, it sucks when you come to a message board and get attacked for sharing information, whether it’s facts, opinions, analysis, or guesses. Some people just have to control the narrative, whether it’s to manipulate others or whatever.